Home  »  Hot Stocks   »  Analyzing the Price-to-Earnings Ratio of Acer Ther...

Analyzing the Price-to-Earnings Ratio of Acer Therapeutics Inc. (ACER)

The 36-month beta value for ACER is also noteworthy at 0.60. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for ACER is $9.67, which is $10.1 above than the current price. The public float for ACER is 12.48M, and at present, short sellers hold a 8.77% of that float. The average trading volume of ACER on May 25, 2023 was 324.38K shares.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


ACER) stock’s latest price update

The stock of Acer Therapeutics Inc. (NASDAQ: ACER) has increased by 5.89 when compared to last closing price of 0.85.Despite this, the company has seen a gain of 11.75% in its stock price over the last five trading days.

ACER’s Market Performance

Acer Therapeutics Inc. (ACER) has experienced a 11.75% rise in stock performance for the past week, with a 3.47% rise in the past month, and a -58.33% drop in the past quarter. The volatility ratio for the week is 11.17%, and the volatility levels for the past 30 days are at 8.61% for ACER. The simple moving average for the past 20 days is 12.29% for ACER’s stock, with a -43.48% simple moving average for the past 200 days.

ACER Trading at 0.78% from the 50-Day Moving Average

After a stumble in the market that brought ACER to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.26% of loss for the given period.

Volatility was left at 8.61%, however, over the last 30 days, the volatility rate increased by 11.17%, as shares sank -2.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.11% lower at present.

During the last 5 trading sessions, ACER rose by +11.75%, which changed the moving average for the period of 200-days by -41.56% in comparison to the 20-day moving average, which settled at $0.8005. In addition, Acer Therapeutics Inc. saw -64.14% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ACER starting from Schelling Chris, who purchase 819,672 shares at the price of $1.22 back on Nov 29. After this action, Schelling Chris now owns 2,712,529 shares of Acer Therapeutics Inc., valued at $1,000,000 using the latest closing price.

ASELAGE STEVE, the Director of Acer Therapeutics Inc., purchase 409,836 shares at $1.22 during a trade that took place back on Nov 29, which means that ASELAGE STEVE is holding 483,741 shares at $500,000 based on the most recent closing price.

Stock Fundamentals for ACER

The liquidity ratio also appears to be rather interesting for investors as it stands at 0.16.


In summary, Acer Therapeutics Inc. (ACER) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.